Abstract
The effects of phenformin plus ethylœstrenol and metformin plus ethylœstrenol on serum-cholesterol, platelet stickiness, and fibrinolysis were compared in ten arteriopathic patients in a trial lasting 15 months. Blood fibrinolytic activity was increased by about 50% by both combinations of drugs. Platelet stickiness and serum-cholesterol levels were reduced by the phenformin combination but were increased by the metformin combination. Reduction of platelet stickiness by phenformin plus ethylœstrenol has been maintained in patients of an earlier series who have been followed for 14-24 months. Contrasted with clofibrate and with metformin plus ethylœstrenol, phenformin plus ethylœstrenol has favourable and sustained effects on four factors associated with occlusive vascular disease—fibrinolysis, plasma-fibrinogen, platelet stickiness, and serum-cholesterol—and thus seems suitable for trial as a prophylactic agent in survivors of vascular occlusions.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
